BACKGROUND: MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. PROCEDURES: MK-2206 was tested against the PPTP in vitro panel using a 96-hour exposure (1.0 nM-10 µM), and in vivo using thrice weekly dosing for a planned 4 weeks at its maximum tolerated dose (MTD) of 180 mg/kg. RESULTS: In vitro, the median relative IC(50) value for MK-2206 was 2.2 µM. Four cell lines with IC(50) values < 200 nM included two ALL cell lines (COG-LL-317 and RS4;11), an AML cell line with an activating KIT mutation (Kasumi-1), and a Ewing sarcoma cell line (CHLA-10). In vivo, MK-2206 induced significant differences in EFS distribution compared to control in 12 of 29 (41%) of the evaluable solid tumor xenografts and in 2 of 8 (25%) of the evaluable ALL xenografts. Significant differences in EFS distribution were most frequently noted in the osteosarcoma panel (6 of 6). A single solid tumor xenograft (OS-31) had a greater than twofold increase in time to event compared to control animals, with all other solid tumor xenografts showing lesser degrees of tumor growth inhibition. Objective responses were not observed for either the solid tumor or ALL xenografts. CONCLUSIONS: MK-2206 showed its most consistent activity in vitro against ALL cell lines and in vivo against osteosarcoma xenografts. However, no objective responses were observed in solid tumor or ALL xenografts. Further preclinical work evaluating MK-2206 in pediatric models in the combination therapy setting may contribute to its pediatric development.
BACKGROUND:MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer. PROCEDURES: MK-2206 was tested against the PPTP in vitro panel using a 96-hour exposure (1.0 nM-10 µM), and in vivo using thrice weekly dosing for a planned 4 weeks at its maximum tolerated dose (MTD) of 180 mg/kg. RESULTS: In vitro, the median relative IC(50) value for MK-2206 was 2.2 µM. Four cell lines with IC(50) values < 200 nM included two ALL cell lines (COG-LL-317 and RS4;11), an AML cell line with an activating KIT mutation (Kasumi-1), and a Ewing sarcoma cell line (CHLA-10). In vivo, MK-2206 induced significant differences in EFS distribution compared to control in 12 of 29 (41%) of the evaluable solid tumor xenografts and in 2 of 8 (25%) of the evaluable ALL xenografts. Significant differences in EFS distribution were most frequently noted in the osteosarcoma panel (6 of 6). A single solid tumor xenograft (OS-31) had a greater than twofold increase in time to event compared to control animals, with all other solid tumor xenografts showing lesser degrees of tumor growth inhibition. Objective responses were not observed for either the solid tumor or ALL xenografts. CONCLUSIONS:MK-2206 showed its most consistent activity in vitro against ALL cell lines and in vivo against osteosarcoma xenografts. However, no objective responses were observed in solid tumor or ALL xenografts. Further preclinical work evaluating MK-2206 in pediatric models in the combination therapy setting may contribute to its pediatric development.
Authors: Ruth Ho; Angelika Eggert; Tomoro Hishiki; Jane E Minturn; Naohiko Ikegaki; Patricia Foster; Anna Marie Camoratto; Audrey E Evans; Garrett M Brodeur Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: Donghwa Kim; Han C Dan; Sungman Park; Lin Yang; Qiyuan Liu; Satoshi Kaneko; Jinying Ning; Lili He; Hua Yang; Mei Sun; Santo V Nicosia; Jin Q Cheng Journal: Front Biosci Date: 2005-01-01
Authors: Natalia L M Liem; Rachael A Papa; Christopher G Milross; Michael A Schmid; Mayamin Tajbakhsh; Seoyeon Choi; Carole D Ramirez; Alison M Rice; Michelle Haber; Murray D Norris; Karen L MacKenzie; Richard B Lock Journal: Blood Date: 2004-02-05 Impact factor: 22.113
Authors: Hans-Guido Wendel; Elisa De Stanchina; Jordan S Fridman; Abba Malina; Sagarika Ray; Scott Kogan; Carlos Cordon-Cardo; Jerry Pelletier; Scott W Lowe Journal: Nature Date: 2004-03-18 Impact factor: 49.962
Authors: H S Friedman; O M Colvin; S X Skapek; S M Ludeman; G B Elion; S C Schold; P F Jacobsen; L H Muhlbaier; D D Bigner Journal: Cancer Res Date: 1988-08-01 Impact factor: 12.701
Authors: Beverly A Teicher; Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Anne Monks; Joel Morris Journal: Mol Cancer Ther Date: 2015-09-08 Impact factor: 6.261
Authors: Marina Y Konopleva; Roland B Walter; Stefan H Faderl; Elias J Jabbour; Zhihong Zeng; Gautam Borthakur; Xuelin Huang; Tapan M Kadia; Peter P Ruvolo; Jennie B Feliu; Hongbo Lu; Lakiesha Debose; Jan A Burger; Michael Andreeff; Wenbin Liu; Keith A Baggerly; Steven M Kornblau; L Austin Doyle; Elihu H Estey; Hagop M Kantarjian Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531
Authors: C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Lock; Richard Gorlick; E Anders Kolb; Raushan T Kurmasheva; Stephen T Keir; John M Maris; Catherine A Billups; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2012-09-21 Impact factor: 3.167
Authors: Maryam Fouladi; John P Perentesis; Christine L Phillips; Sarah Leary; Joel M Reid; Renee M McGovern; Ashish M Ingle; Charlotte H Ahern; Matthew M Ames; Peter Houghton; L Austin Doyle; Brenda Weigel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2014-03-24 Impact factor: 3.167
Authors: Ankita Gupte; Emma K Baker; Soo-San Wan; Elizabeth Stewart; Amos Loh; Anang A Shelat; Cathryn M Gould; Alistair M Chalk; Scott Taylor; Kurt Lackovic; Åsa Karlström; Anthony J Mutsaers; Jayesh Desai; Piyush B Madhamshettiwar; Andrew C W Zannettino; Chris Burns; David C S Huang; Michael A Dyer; Kaylene J Simpson; Carl R Walkley Journal: Clin Cancer Res Date: 2015-04-10 Impact factor: 12.531